The effect of chronic CRF1 receptor blockade on the central CCK systems of Fawn-Hooded rats

Regulatory Peptides

Volumn 116, Issue 1-3, 2003, Pages 27-33

  Lodge, Daniel J ^a,b   Lawrence, Andrew J ^a,c  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

Antalarmin; CRF; Neurochemistry

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; ANTALARMIN; BACITRACIN; BENZYLSULFONYL FLUORIDE; CHOLECYSTOKININ; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; DEVAZEPIDE; ENZYME INHIBITOR; MESSENGER RNA; PEPTIDASE INHIBITOR; PHOSPHORAMIDON; UNCLASSIFIED DRUG; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG EFFECT; DRUG RECEPTOR BINDING; EMOTION; LIMBIC SYSTEM; NERVE FIBER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RAT STRAIN; REWARD; THALAMOCORTICAL TRACT; ANIMAL; BRAIN; DRUG ANTAGONISM; GENETICS; METABOLISM;

ANIMALS; BRAIN; CHOLECYSTOKININ; CORTICOTROPIN-RELEASING HORMONE; PYRIMIDINES; PYRROLES; RATS; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; RNA, MESSENGER;

EID: 0242361256     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-0115(03)00189-7     Document Type: Article

References (57)

1. 1 receptor antagonist antalarmin reduces volitional ethanol consumption in isolation-reared Fawn-Hooded rats. Neuroscience. 117:2003;243-247.
2. Chalmers D.T., Lovenberg T.W., Grigoriadis D.E., Behan D.P., De Souza E.B. Corticotrophin-releasing factor receptors: from molecular biology to drug design. Trends. Pharmacol. Sci. 17:1996;166-172.
3. 2 receptors in fear and anxiety. Neurosci. Biobehav. Rev. 25:2001;627-636.
4. Reul J.M., Holsboer F. Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr. Opin. Pharmacol. 2:2002;23-33.
5. Briscoe R.J., Cabrera C.L., Baird T.J., Rice K.C., Woods J.H. Antalarmin blockade of corticotropin releasing hormone-induced hypertension in rats. Brain Res. 881:2000;204-207.
6. Hope P.J., Turnbull H., Farr S., Morley J.E., Rice K.C., Chrousos G.P.et al. Peripheral administration of CRF and urocortin: effects on food intake and the HPA axis in the marsupial Sminthopsis crassicaudata. Peptides. 21:2000;669-677.
7. Sarnyai Z., Shaham Y., Heinrichs S.C. The role of corticotropin- releasing factor in drug addiction. Pharmacol. Rev. 53:2001;209-243.
8. Griebel G. Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? Pharmacol. Ther. 82:1999;1-61.
9. Harro J., Tonissaar M., Eller M. The effects of CRA 1000, a non-peptide antagonist of corticotropin-releasing factor receptor type 1, on adaptive behaviour in the rat. Neuropeptides. 35:2001;100-109.
10. 1 receptor antagonist R121919 depends on innate emotionality in rats. Eur. J. Neurosci. 13:2001;373-380.
11. Hokfelt T., Broberger C., Xu Z.Q., Sergeyev V., Ubink R., Diez M. Neuropeptides - an overview. Neuropharmacology. 39:2000;1337-1356.
12. Lee S., Smith G.W., Vale W., Lee K.F., Rivier C. Mice that lack corticotropin-releasing factor (CRF) receptors type 1 show a blunted ACTH response to acute alcohol despite upregulated constitutive hypothalamic CRF gene expression. Alcohol. Clin. Exp. Res. 25:2001;427-433.
13. Rivier C., Lee S. Acute alcohol administration stimulates the activity of hypothalamic neurons that express corticotropin-releasing factor and vasopressin. Brain Res. 726:1996;1-10.
14. Lee S., Rivier C. Alcohol increases the expression of type 1, but not type 2α corticotropin-releasing factor (CRF) receptor messenger ribonucleic acid in the rat hypothalamus. Mol. Brain Res. 52:1997;78-89.
15. Cowen M.S., Rezvani A.H., Jarrott B., Lawrence A.J. Ethanol consumption by Fawn-Hooded rats following abstinence: effect of naltrexone and changes in μ-opioid receptor density. Alcohol. Clin. Exp. Res. 23:1999;1008-1014.
16. Woods S.C., Seeley R.J., Porte D. Jr., Schwartz M.W. Signals that regulate food intake and energy homeostasis. Science. 280:1998;1378-1383.
17. Vaccarino F.J., Vaccarino A.L. Antagonism of cholecystokinin function in the rostral and caudal nucleus accumbens: differential effects on brain stimulation reward. Neurosci. Lett. 97:1989;151-156.
18. Rehfeld J.F. CCK and anxiety. Dourish C.T., Cooper S.J., Iversen S.D., Iversen L.L. Multiple cholecystokinin receptors in the CNS. 1992;117-120 Oxford Univ. Press, London.
19. Gillis R.A., Quest J.A., Pagani F.D., Souza J.D., Da Silva A.M., Jensen R.T.et al. Activation of central nervous system cholecystokinin receptors stimulates respiration in the cat. J. Pharmacol. Exp. Ther. 224:1983;408-414.
20. Fossa A.A., DePasquale M.J., Morrone J., Zorn S.H., Bryce D., Lowe J.A. et al. Cardiovascular effects of cholecystokinin-4 are mediated by the cholecystokinin-B receptor subtype in the conscious guinea pig and dog. J. Pharmacol. Exp. Ther. 281:1997;180-187.
21. Singh L., Lewis A.S., Field M.J., Hughes J., Woodruff G.N. Evidence for an involvement of the brain cholecystokinin B receptor in anxiety. Proc. Natl. Acad. Sci. 88:1991;1130-1133.
22. Derrien M., McCort-Tranchepain I., Ducos B., Roques B.P., Durieux C. Heterogeneity of CCK-B receptors involved in animal models of anxiety. Pharmacol. Biochem. Behav. 49:1994;133-141.
23. Bradwejn J., Koszycki D. The cholecystokinin hypothesis of anxiety and panic disorder. Ann. N. Y. Acad. Sci. 713:1994;273-282.
24. Rex A., Barth T., Voigt J.P., Domeney A.M., Fink H. Effects of cholecystokinin tetrapeptide and sulfated cholecystokinin octapeptide in rat models of anxiety. Neurosci. Lett. 172:1994;139-142.
25. Rex A., Fink H., Marsden C.A. Effects of BOC-CCK-4 and L 365.260 on cortical 5-HT release in guinea-pigs on exposure to the elevated plus maze. Neuropharmacology. 33:1994;59-65.
26. Singh L., Field M.J., Hughes J., Mezies R., Oles R.J., Vass C.A.et al. The behavioural properties of CI-988, a selective cholecystokinin B receptor antagonist. Br. J. Pharmacol. 104:1991;239-245.
27. Matto V., Harro J., Allikmets L. The effects of cholecystokinin A and B receptor antagonists on exploratory behaviour in the elevated zero-maze in rat. Neuropharmacology. 36:1997;389-396.
28. Josselyn S.A., De Cristofaro A., Vaccarino F.J. Evidence for CCK-A receptor involvement in the acquisition of conditioned activity produced by cocaine in rats. Brain Res. 763:1997;93-102.
29. Massey B.W., Vanover K.E., Woolverton W.L. Effects of cholecystokinin antagonists on the discriminative stimulus effects of cocaine in rats and monkeys. Drug Alcohol Depend. 34:1994;105-111.
30. Josselyn S.A., Vaccarino F.J. Interaction of CCKB receptors with amphetamine in responding for conditioned rewards. Peptides. 16:1995;959-964.
31. Vaccarino F.J., Rankin J. Nucleus accumbens cholecystokinin (CCK) can either attenuate or potentiate amphetamine-induced locomotor activity: evidence for rostral-caudal differences in accumbens CCK function. Behav. Neurosci. 103:1989;831-836.
32. Crespi F. The role of cholecystokinin (CCK), CCK-A or CCK-B receptor antagonists in the spontaneous preference for drugs of abuse (alcohol or cocaine) in naive rats. Methods Find. Exp. Clin. Pharmacol. 20:1998;679-697.
33. Crespi F., Corsi M., England T., Ratti E., Trist D.G., Gaviraghi G. Spontaneous preference for ethanol in naive rats is influenced by cholecystokinin A receptor antagonism. Alcohol. 14:1997;327-332.
34. Wilson J., Little H.J. CCK-B antagonists protect against some aspects of the ethanol withdrawal syndrome. Pharmacol. Biochem. Behav. 59:1998;967-973.
35. Crawley J.N. Cholecystokinin-dopamine interactions. Trends Pharmacol. Sci. 12:1991;232-236.
36. Lança A.J., De Cabo C., Arifuzzaman A.I., Vaccarino F.J. Cholecystokinergic innervation of nucleus accumbens subregions. Peptides. 19:1998;859-868.
37. Seroogy K.B., Dangaran K., Lim S., Haycock J.W., Fallon J.H. Ventral mesencephalic neurons containing both cholecystokinin- and tyrosine hydroxylase-like immunoreactivities project to forebrain regions. J. Comp. Neurol. 279:1989;397-414.
38. Seroogy K.B., Fallon J.H. Forebrain projections from cholecystokinin- like immunoreactive neurons in the rat midbrain. J. Comp. Neurol. 279:1989;415-435.
39. Lodge D.J., Short J.L., Mercer L.D., Beart P.M., Lawrence A.J. CCK/dopamine interactions in Fawn-Hooded and Wistar-Kyoto rat brain. Peptides. 21:2000;379-386.
40. Ladurelle N., Keller G., Roques B.P., Dauge V. Effects of CCK8 and of the CCKB-selective agonist BC264 on extracellular dopamine content in the anterior and posterior nucleus accumbens: a microdialysis study in freely moving rats. Brain Res. 628:1993;254-262.
41. Marshall F.H., Barnes S., Hughes J., Woodruff G.N., Hunter J.C. Cholecystokinin modulates the release of dopamine from the anterior and posterior nucleus accumbens by two different mechanisms. J. Neurochem. 56:1991;917-922.
42. Lodge D.J., Lawrence A.J. The neurochemical effects of anxiolytic drugs are dependent on rearing conditions in Fawn-Hooded rats. Prog. neuropsychopharmacol. Biol. Psychiatry. 27:2003;451-458.
43. National Health and Medical Research Council (Aus). Australian code of practice for the care and use of animals for scientific purposes. 6th ed.; 1997. http://www.nhmrc.gov.au/research/awc/code.htm .
44. Lodge D.J., Lawrence A.J. Comparative analysis of the central CCK system in Fawn Hooded and Wistar Kyoto rats: extended localisation of CCK-A receptors throughout the rat brain using a novel radioligand. Regul. Pept. 99:2001;191-201.
45. 28,31]CCK-(25-33): a convenient new aminopeptidase resistant cholecystokinin analogue for radioligand binding and autoradiography. Eur. J. Pharmacol. 191:1990;107-110.
46. Lawrence A.J., Krstew E., Jarrott B. Actions of nitric oxide and expression of the mRNA encoding nitric oxide synthase in rat vagal afferent neurons. Eur. J. Pharmacol. 315:1996;127-133.
47. Burazin T.C., Gundlach A.L. Rapid but transient increases in cholecystokinin mRNA levels in cerebral cortex following amygdaloid-kindled seizures in the rat. Neurosci. Lett. 209:1996;65-68.
48. Paxinos G., Watson C. The rat brain in stereotaxic coordinates. 2nd ed. 1986;Academic Press, USA.
49. Wong M.-.L., Webster E.L., Spokes H., Phu P., Ehrhart-Bornstein M., Bornstein S.et al. Chronic administration of the non-peptide CRH type 1 receptor antagonist antalarmin does not blunt hypothalamic-pituitary-adrenal axis responses to acute immobilization stress. Life Sci. 65:1999;53-58.
50. Van Groen T., Vogt B.A., Wyss J.M. Interconnections between the thalamus and retrosplenial cortex in the rodent brain. Vogt B.A., Gabriel M. Neurobiology of cingulate cortex and limbic thalamus. 1993;123-151 Birkhäuser, Boston.
51. Bentivoglio M., Kultas-Ilinsky K., Ilinsky I. Limbic thalamus: structure, intrinsic organization and connections. Vogt B.A., Gabriel M. Neurobiology of cingulate cortex and limbic thalamus. 1993;71-122 Birkhäuser, Boston.
52. Papez J.W. A proposed mechanism of emotion. Arch. Neurol. Psychiatry. 38:1937;725-734.
53. Cardinal R.N., Parkinson J.A., Hall J., Everitt B.J. Emotion and motivation: the role of the amygdala, ventral striatum, and prefrontal cortex. Neurosci. Biobehav. Rev. 26:2002;321-352.
54. Tekin S., Cummings J.L. Frontal-subcortical neuronal circuits and clinical neuropsychiatry: an update. J. Psychosom. Res. 53:2002;647-654.
55. 1 receptor antagonist. Eur. J. Pharmacol. 323:1997;21-26.
56. Harro J., Wahlstrom G., Oreland L. Cholecystokinin receptor binding after long-term ethanol treatment in rats. Alcohol Alcohol. 29:1994;575-581.
57. Ryder S., Straus E., Lieber C.S., Yalow R.S. Cholecystokinin and enkephalin levels following ethanol administration in rats. Peptides. 2:1981;223-226.